Summary
EudraCT Number: 2008-007308-27
Sponsor's Protocol Code Number: BAY86-5016/13082
National Competent Authority: Czechia - SUKL 
Clinical Trial Type: EEA CTA
Trial Status: Completed
Date on which this record was first entered in the EudraCT database: 2009-03-27
Link: https://www.clinicaltrialsregister.eu/ctr-search/trial/2008-007308-27/CZ/

A. Protocol Information
A.1 Member State Concerned: Czech Republic - SUKL
A.2 EudraCT number: 2008-007308-27
A.3 Full title of the trial: Multi-center, open-label, randomized, parallel-group comparison of cycle control, bleeding pattern, lipid and carbohydrate metabolism of the transdermal contraceptive patch containing 0.55 mg ethinylestradiol and 2.1 mg gestodene (material no. 80876395) in a 21-day regimen vs. a comparator patch EVRA® (0.6 mg ethinylestradiol and 6 mg norelgestromin) in a 21-day regimen for 7 cycles in 400 women
A.3.2 Name or abbreviated title of the trial where available: Transdermal contraceptive patch: EU cycle control study (vs. EVRA) 
A.4.1 Sponsor's protocol code number: BAY86-5016/13082
A.7 Trial is part of a Paediatric Investigation Plan: Information not present in EudraCT
A.8 EMA Decision number of Paediatric Investigation Plan: 

B. Sponsor Information
Sponsor 1
B.1.1 Name of Sponsor: Bayer HealthCare AG
B.1.3.4	Country: Germany
B.3.1 and B.3.2	Status of the sponsor: Commercial
B.4 Source(s) of Monetary or Material Support for the clinical trial:
B.4.1 Name of organisation providing support:
B.4.2 Country:
B.5 Contact point designated by the sponsor for further information on the trial
B.5.1 Name of organisation: 
B.5.2 Functional name of contact point: 

D. IMP Identification
D.IMP: 1
D.1.2 and D.1.3 IMP Role: Test
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: No
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.1 Product name: FC Patch Low
D.3.2 Product code: material no. 80876395
D.3.4 Pharmaceutical form: Transdermal patch
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Transdermal use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: Ethinylestradiol
D.3.9.1 CAS number: 57-63-6
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 0.55 
D.3.8 INN - Proposed INN: Gestodene
D.3.9.1 CAS number: 60282873
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 2.1 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No
D.IMP: 2
D.1.2 and D.1.3 IMP Role: Comparator
D.2 Status of the IMP to be used in the clinical trial
D.2.1 IMP to be used in the trial has a marketing authorisation: Yes
D.2.1.1.1 Trade name: EVRA
D.2.1.1.2 Name of the Marketing Authorisation holder: JANSSEN-CILAG INTERNATIONAL N.V.
D.2.1.2 Country which granted the Marketing Authorisation: European Union
D.2.5 The IMP has been designated in this indication as an orphan drug in the Community: No
D.2.5.1 Orphan drug designation number: 
D.3 Description of the IMP
D.3.4 Pharmaceutical form: Transdermal patch
D.3.4.1 Specific paediatric formulation: Information not present in EudraCT
D.3.7 Routes of administration for this IMP:
Transdermal use
D.3.8 to D.3.10 IMP Identification Details (Active Substances)
D.3.8 INN - Proposed INN: Ethinylestradiol
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 0.6 
D.3.8 INN - Proposed INN: Norelgestomin
D.3.10 Strength
D.3.10.1 Concentration unit: mg milligram(s)
D.3.10.2 Concentration type: equal
D.3.10.3 Concentration number: 6 
D.3.11 The IMP contains an
D.3.11.1 Active substance of chemical origin: Yes
D.3.11.2 Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP): No
D.3.11.3 Advanced Therapy IMP (ATIMP): Information not present in EudraCT
D.3.11.3.1 Somatic cell therapy medicinal product: No
D.3.11.3.2 Gene therapy medical product: No
D.3.11.3.3 Tissue Engineered Product: Information not present in EudraCT
D.3.11.3.4 Combination ATIMP (i.e. one involving a medical device): Information not present in EudraCT
D.3.11.3.5 Committee on Advanced therapies (CAT) has issued a classification for this product: Information not present in EudraCT
D.3.11.4 Combination product that includes a device, but does not involve an Advanced Therapy: Information not present in EudraCT
D.3.11.5 Radiopharmaceutical medicinal product: No
D.3.11.6 Immunological medicinal product (such as vaccine, allergen, immune serum): No
D.3.11.7 Plasma derived medicinal product: No
D.3.11.8 Extractive medicinal product: No
D.3.11.9 Recombinant medicinal product: Information not present in EudraCT
D.3.11.10 Medicinal product containing genetically modified organisms: No
D.3.11.11 Herbal medicinal product: No
D.3.11.12 Homeopathic medicinal product: No
D.3.11.13 Another type of medicinal product: No

D.8 Information on Placebo

E. General Information on the Trial
E.1 Medical condition or disease under investigation
E.1.1 Medical condition(s) being investigated: Prevention of pregnancy
MedDRA Classification
E.1.2 Medical condition or disease under investigation:
E.1.2 Version: 9.1
E.1.2 Level: LLT
E.1.2 Classification code: 10060346
E.1.2 Term: Transdermal contraception
E.1.3 Condition being studied is a rare disease: No
E.2 Objective of the trial
E.2.1 Main objective of the trial: The primary objective is to investigate the bleeding pattern and cycle control parameters of the transdermal contraceptive patch FC Patch Low (material no. 80876395 containing 0.55 mg EE and 2.1 mg GSD) in comparison to the EVRA patch (containing 0.6 mg EE and 6 mg NGMN).
E.2.2 Secondary objectives of the trial: The secondary objectives are the contraceptive efficacy, safety profile (including lipid/carbohydrate metabolism), and population pharmacokinetics of FC Patch Low in comparison to the EVRA patch.

Additionally, compliance and subjective assessment of the treatment will be evaluated as secondary objectives.
E.2.3 Trial contains a sub-study: No
E.3 Principal inclusion criteria: 1.Signed and dated informed consent
2.Healthy woman requesting contraception
3.Age: 18 – 35 years (inclusive); smokers must not be older than 30 years at the time of informed consent 
4.Normal cervical smear not requiring further follow-up (a cervical smear has to be taken at screening visit or a normal result has to be documented within the previous 6 months) 
5.History of regular cyclic menstrual periods  

E.4 Principal exclusion criteria: Pregnancy or lactation, obesity (BMI > 30), hypersensitivity to any ingredient of the study drug, significant skin reaction to transdermal preparations, any diseases/conditions that can compromise the functions of the body system (resulting in altered absorption/ accumulation/ metabolism/ excretion of the study drug), any diseases/ conditions that may worsen under hormonal treatment.
E.5 End points
E.5.1 Primary end point(s): Cycle control parameters and bleeding pattern indices 
E.6 and E.7 Scope of the trial
E.6 Scope of the Trial
E.6.1 Diagnosis: Information not present in EudraCT
E.6.2 Prophylaxis: Information not present in EudraCT
E.6.3 Therapy: Information not present in EudraCT
E.6.4 Safety: Yes
E.6.5 Efficacy: Yes
E.6.6 Pharmacokinetic: Yes
E.6.7 Pharmacodynamic: Information not present in EudraCT
E.6.8 Bioequivalence: Information not present in EudraCT
E.6.9 Dose response: Information not present in EudraCT
E.6.10 Pharmacogenetic: Information not present in EudraCT
E.6.11 Pharmacogenomic: Information not present in EudraCT
E.6.12 Pharmacoeconomic: Information not present in EudraCT
E.6.13 Others: Information not present in EudraCT
E.7 Trial type and phase 
E.7.1 Human pharmacology (Phase I): No
E.7.1.1 First administration to humans: Information not present in EudraCT
E.7.1.2 Bioequivalence study: Information not present in EudraCT
E.7.1.3 Other: Information not present in EudraCT
E.7.1.3.1 Other trial type description: 
E.7.2 Therapeutic exploratory (Phase II): No
E.7.3 Therapeutic confirmatory (Phase III): Yes
E.7.4 Therapeutic use (Phase IV): No
E.8 Design of the trial
E.8.1 Controlled: Yes
E.8.1.1 Randomised: Yes
E.8.1.2 Open: Yes
E.8.1.3 Single blind: No
E.8.1.4 Double blind: No
E.8.1.5 Parallel group: Yes
E.8.1.6 Cross over: No
E.8.1.7 Other: No
E.8.2 Comparator of controlled trial
E.8.2.1 Other medicinal product(s): Yes
E.8.2.2 Placebo: No
E.8.2.3 Other: No
E.8.3 The trial involves single site in the Member State concerned: Information not present in EudraCT
E.8.4 The trial involves multiple sites in the Member State concerned: Information not present in EudraCT
E.8.4.1 Number of sites anticipated in Member State concerned: 9
E.8.5 The trial involves multiple Member States: Yes
E.8.5.1 Number of sites anticipated in the EEA: 30
E.8.6 Trial involving sites outside the EEA
E.8.6.1 Trial being conducted both within and outside the EEA: No
E.8.6.2 Trial being conducted completely outside of the EEA: Information not present in EudraCT
E.8.7 Trial has a data monitoring committee: No
E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial: 
E.8.9 Initial estimate of the duration of the trial
E.8.9.1 In the Member State concerned years: 1
E.8.9.1 In the Member State concerned months: 9
E.8.9.1 In the Member State concerned days: 0
E.8.9.2 In all countries concerned by the trial years: 1
E.8.9.2 In all countries concerned by the trial months: 9
E.8.9.2 In all countries concerned by the trial days: 0

F. Population of Trial Subjects
F.1 Age Range
F.1.1 Trial has subjects under 18: No
F.1.1.1 In Utero: Information not present in EudraCT
F.1.1.2 Preterm newborn infants (up to gestational age < 37 weeks): Information not present in EudraCT
F.1.1.3 Newborns (0-27 days): Information not present in EudraCT
F.1.1.4 Infants and toddlers (28 days-23 months): Information not present in EudraCT
F.1.1.5 Children (2-11years): Information not present in EudraCT
F.1.1.6 Adolescents (12-17 years): Information not present in EudraCT
F.1.2 Adults (18-64 years): Yes
F.1.3 Elderly (>=65 years): No
F.2 Gender
F.2.1 Female: Yes
F.2.2 Male: No
F.3 Group of trial subjects
F.3.1 Healthy volunteers: Yes
F.3.2 Patients: No
F.3.3 Specific vulnerable populations: Yes
F.3.3.1 Women of childbearing potential not using contraception  
(For clinical trials recorded in the database before the 10th March 2011 this question read: "Women of childbearing potential" and
did not include the words "not using contraception". An answer of yes could have included women of child bearing potential whether
or not they would be using contraception. The answer should therefore be understood in that context. This trial was recorded in the
database on 2009-03-27) : Yes
F.3.3.2 Women of child-bearing potential using contraception: Yes
F.3.3.3 Pregnant women: No
F.3.3.4 Nursing women: No
F.3.3.5 Emergency situation: No
F.3.3.6 Subjects incapable of giving consent personally: No
F.3.3.7 Others: No
F.4 Planned number of subjects to be included
F.4.1 In the member state: 230
F.4.2 For a multinational trial
F.4.2.1 In the EEA: 400
F.4.2.2 In the whole clinical trial: 400

G. Investigator Networks to be involved in the Trial


N. Review by the Competent Authority or Ethics Committee in the country concerned
N. Competent Authority Decision: Authorised
N. Date of Competent Authority Decision: 2009-05-07
N. Ethics Committee Opinion of the trial application: Favourable
N. Ethics Committee Opinion: Reason(s) for unfavourable opinion:
N. Date of Ethics Committee Opinion: 2009-05-06

P. End of Trial
P. End of Trial Status: Completed

